AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00461487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Families Talking Together
Description: The intervention will take place in a primary healthcare clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. A mother of the adolescent will meet with a social work interventionist for approximately 25 minutes while her child is being examined by the physician. During this time, the intervention will be delivered to the mother. At the conclusion of the session, the mother will be given reference materials to take home and tasks to perform to facilitate discussions about sex with her adolescent. There will be three follow-up booster sessions administered through phone calls to increase completion probabilities of the tasks. The target behavior is sexual activity in adolescents.
Study NCT03975452 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reduced radiation volumes
Description: Patient treated with reduced radiation volumes with the exclusion of elective pelvic nodal irradiation
Study NCT00480584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Levels 1 through 4: 1000 mg/m\^2
Study NCT00480584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Level 1: 500 mg/m\^2; Level 2: 825 mg/m\^2; Level 3: 1000 mg/m\^2; Level 4: 1250 mg/m\^2
Study NCT00480584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Levels 1 through 4: 100 mg
Study NCT03832296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight-Loss Maintenance
Description: Over the course of the first 6-months, participants will build their self-efficacy to maintain weight loss on their own, empowered to do what is needed to achieve personal goals and long-term behavior change (months 7-18). The first 6 months of I-CAN will prepare participants for successful independent weight-loss maintenance in months 7-18. During the 12-month independent weight-loss maintenance phase participants exercise on their own and maintain their weight loss (or increase weight loss if they choose) with the only contact from interventionists being two newsletters at months 9 and 15.
Study NCT03832296 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education (Attention Control)
Description: Participants in the control group will attend an individual session during month 1, and a monthly face-to-face group meeting during months 2-6. The sessions will provide attention, social interaction, and physician-based health education. Participants will receive a newsletter during months 9 and 15.
Study NCT01783587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Taken orally once per day
Study NCT01783587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 15 mg/m2, given intravenously once per week
Study NCT01783587 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Daily, Monday-Friday, for six to seven weeks
Study NCT05679856 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated single vocal cord irradiation
Description: Only the affected vocal cord with additional margin to account for motion and setup errors will receive 58.08Gy/16 fractions using IMRT/VMAT technique
Study NCT05679856 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole laryngeal radiotherapy
Description: The whole larynx from lower border of hyoid bone to lower border of cricoid cartilage will receive 63Gy/28 fractions using IMRT/VMAT technique
Study NCT01748487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone intravitreal implant (OZURDEX)
Description: intravitreal implant
Study NCT00822588 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sangvia® System
Description: Sangvia® Intra- and Post-op System
Study NCT04173065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VK2809
Description: Capsule
Study NCT04173065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Capsule
Study NCT04723186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1002 for Injection
Description: MT1002 will be initiated as close to the start of PCI as possible. MT1002 should be initiated during diagnostics angiography when indication for PCI is confirmed, provided the PCI is indicated right after the coronary angiography. PCI can start after MT1002 initiation as soon as ACT is confirmed to be ≥ 200 sec or within 30 min after MT1002 starts, whichever occurs first. MT1002 will be administered by an intravenous injection of 0.90 mg/kg, 1.2 mg/kg, or 0.6 mg/kg (depending on the dose selected for the cohort) prior to the PCI procedure, immediately followed by an IV infusion of 1.8 mg/kg/hour, 2.3 mg/kg/hour, or 1.2 mg/kg/hour (depending on the dose selected for the cohort) until completion of the procedure. At completion of PCI, subjects will be continued on IV MT1002 for 4 hours from infusion start.
Study NCT01692691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine IV - Day 1
Study NCT01692691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Carmustine IV- Day 2
Study NCT01692691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neulasta
Description: Neulasta SC - Day 3
Study NCT01562951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADALIMUMAB
Description: Adalimumab at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly.
Study NCT01562951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PLACEBO at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly
Study NCT02742766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3008356
Description: This intervention is available as 0.5, 1, 5, and 25 mg white oral tablet. The formulation will be used to administer dose of 5 mg, 10 mg, 30 mg, 45 mg, 75 mg, 90 mg, 125 mg, 180 mg, 200 mg, and 250 mg total daily dose during the study.
Study NCT02742766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This intervention is available as white oral tablet. The formulation will be used as a matching placebo for GSK3008356 during the study.
Study NCT02518022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin for beer
Study NCT05198687 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long implant and partial overdentures
Description: insertion of long implants anterior to the maxillary sinus to retain partial overdentures
Study NCT01544010 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate TTM-Tailored Feedback Report
Description: Tailored printed feedback report based on assessment of stages of change, Pros, Cons, and Temptations were delivered at baseline, 6 months and 12 months.
Study NCT05198687 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus lift and long implant
Description: performing sinus lift surgical procedure with simultaneous placement of long implants to support screw-retained prosthesis
Study NCT05198687 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: short implant without sinus lift
Description: placement of short implants in the remaining bone above maxillary sinus to support screw-retained prosthesis without performing sinus lift
Study NCT05198687 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Partial overdentures
Description: Distal extension metallic partial dentures retained by attachments to the implants
Study NCT05198687 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metal ceramic prosthesis on long implants
Description: porcelain fused to metal fixed screw-retained prosthesis supported by long implants
Study NCT05198687 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metal ceramic prosthesis on short implants
Description: porcelain fused to metal fixed screw-retained prosthesis supported by short implants
Study NCT02907138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Yoga
Study NCT02907138 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (physical therapy)
Study NCT01544010 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Full TTM-Tailored Feedback Report
Description: Tailored print feedback report based on assessment of Stages, Pros, Cons, Temptations, 10 Processes of Change were delivered at baseline, 6 months and 12 months.
Study NCT00223678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Rapamycin will start within 24 hours of last calcineurin inhibitors (Cya, Prograf). Initial dose of Rapamune 10mg will be given for 3 days and then dose will be adjusted to attain a target whole blood trough of 5-15
Study NCT03674125 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLS-6150
Description: Group 1: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, healthy volunteers); Group 2: GLS-6150 1.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 3: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 4: GLS-6150 2.0 mg at 0, 8, and 24 weeks (N=8, previously treated for HCV infection)
Study NCT06220903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex Decongestive Therapy
Description: 1. Manual Lymph Drainage: Cervical region lymph drainage and abdominal region lymph drainage (especially combined with abdominal breathing) were applied.~2. Skin Care: Moisturizing creams with a pH of 5.5 were applied to the extremities before bandaging.~3. Multilayer Bandaging: Short pull bandage application was applied in a gradient manner.~4. Exercise: Joint range of motion exercises, breathing exercises (abdominal breathing), decongestive exercises, and self-drainage techniques were taught.~5. Compression Stocking: After the decongestion phase was over, flat knit compression stockings were recommended according to the patient's extremity.
Study NCT02824263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPAP withdrawal
Description: CPAP is discontinued for 3 nights.
Study NCT00373750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Family Spirit Intervention
Description: The Family Spirit Intervention was developed over a decade through community-based participatory research.The intervention content included 43 structured lessons and followed a culturally congruent format.
Study NCT02928107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-HS
Description: Patients will be given information on the Tele-HS and given access to take the screening at home or in-office, depending on arm.
Study NCT02928107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCP encouragement
Description: Patients will or will not either receive PCP encouragement to do the Tele-HS.
Study NCT03739437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Contingency Management
Description: Participants will be offered six tobacco cessation telephone counseling sessions, 12 weeks of nicotine replacement therapy, and a smartphone app that remotely verifies participant identity and smoking abstinence and automatically credits a gift card account for evidence of smoking abstinence.
Study NCT03739437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Participants will be offered six tobacco cessation telephone counseling sessions, 12 weeks of nicotine replacement therapy, and incentives that are not contingent on smoking abstinence (incentives are yoked to participants in the contingency management group).
Study NCT03739437 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants will be offered six tobacco cessation telephone counseling sessions, 12 weeks of nicotine replacement therapy, and incentives that are not contingent on smoking abstinence (incentives are yoked to participants in the contingency management group).
Study NCT04586582 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ST-segment resolution <40.15%
Description: Forty-two STEMI patients with single-branch coronary artery stenosis or occlusion were enrolled. ST-segment elevations were measured at emergency admission and at 24 h after PCI. Late gadolinium-enhanced cardiac magnetic resonance imaging (CMR-LGE) was performed 7 days after PCI to evaluate myocardial scars.
Study NCT00145925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Perindopril-indapamide
Study NCT00145925 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gliclazide MR-based glucose lowering
Study NCT00359190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: GW572016 ditosylate salt (lapatinib) will be given as 250 mg tablets via oral route
Study NCT01487356 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Colonoscopies were conducted as per the endoscopist's usual practice. No change in protocol was expected.
Study NCT01959048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplantation
Study NCT01220232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abacavir/Lamivudine
Description: Abacavir/Lamivudine 600/300 mg QD for 5 days
Study NCT01220232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir/Lamivudine
Description: Abacavir/Lamivudine 600/300 mg QD for 10 days
Study NCT01220232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine
Description: Lersivirine 750 mg QD for 10 days
Study NCT02905760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Furosemide: Special LASILIX (250 mg/25 ml) solution for injection reconditioned glass bottle like penicillin of 80mg/8mL. Injection by slow intravenous (1 to 2 minutes per 80mg vial)
Study NCT02905760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo filling
Description: Placebo filling: Glucose 5%, 500mL infused over 30 minutes.
Study NCT02905760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo furosemide
Description: Placebo furosemide: glucose 5% for injection reconditioned glass bottle like penicillin of 80mg/8mL. Injection by slow intravenous (1 to 2 minutes per 80mg vial).
Study NCT02905760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vascular filling
Description: Vascular filling: Sodium 0.9% 500mL infused over 30 minutes.
Study NCT03528863 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Mindfulness Meditation
Description: Receive web-based mindfulness meditation
Study NCT03528863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03587857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Health Application
Description: This mobile health app is a modular, adaptive, and personalized intervention delivered via a mobile phone. It is grounded in the Information Motivation Behavioral Skills (IMB) model. It was created in collaboration with YLWH (18-29 years-old) using a Human-Centered Design approach to help improve engagement in HIV care among this age group.
Study NCT00528892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: switching PI to raltegravir
Study NCT00528892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: boosted PI
Description: continue on boosted-PI
Study NCT03200340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: Oral administration of EC-18 twice daily
Study NCT03200340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match EC-18 capsule administration
Study NCT03186196 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet containing Folate
Study NCT03186196 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Diet containing Folate
Study NCT01163721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Ranolazine ER 1000 mg (two 500 mg tablets) administered orally twice daily
Study NCT01544010 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced TTM+Addiction Tailored Feedback Report
Description: Tailored print feedback report based on assessment of Addiction level (# cigarettes/day),Stages, Pros, Cons, Temptations, 10 Processes of Change were delivered at baseline, 6 months and 12 months.
Study NCT03763838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Six weeks of daily self-administered relaxing acupressure. Instructions will be provided for how to perform acupressure on self. A tool (AcuWand) will be provided to help participants apply the right amount of pressure on the appropriate points on their bodies. These are points that are recognized as effective in Traditional Chinese Medicine (TCM).
Study NCT01163721 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ranolazine administered orally twice daily
Study NCT04612387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-body therapy
Description: Online yoga, meditation and nutrition tips.
Study NCT01295281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric POBE 2.0
Description: To be used at least twice daily, during 7 days. Treatment period 1 and 2 last 7 days, respectively.
Study NCT01295281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric PVC
Description: To be used at least twice daily, during 7 days. Treatment period 1 and 2 last 7 days, respectively.
Study NCT03475017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Supplement A
Description: The patients will receive 3 capsules per day containing 500mg of curcumin and 5mg of piperine for 4 weeks
Study NCT03475017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Supplement B
Description: The patients will receive 3 capsules of placebo per day containing 500mg of maize starch for 4 weeks
Study NCT03189043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antimicrobial Surface
Description: Antimicrobial Surface
Study NCT04029935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Fatigue
Description: Maximal cycling effort for 30s (Wingate modified)
Study NCT04029935 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: time-matched task (sitting on the bike without pedalling)
Study NCT01507558 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Administration of dexamethasone to SFA/popliteal adventitia
Description: Following a balloon angioplasty or atherectomy of a stenotic TASC II A, B, or C lesion in the superficial femoral or popliteal artery, a Bullfrog Micro-Infusion Catheter will be used to infuse 0.96 mg dexamethasone per cm arterial lesion.
Study NCT01928498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel Eluting Balloon Angioplasty
Study NCT01928498 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty (PTA)
Study NCT03171831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan（4 mg/kg/day,4 days）
Study NCT03171831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide（50 mg/kg/day,4 days）
Study NCT03171831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine（50 mg/m2/day,3 days）
Study NCT03171831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil（0.25g/day）
Study NCT03171831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus（0.03mg/kg/day）
Study NCT03171831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate（15mg/m2 on day +1,10mg/m2 on day +3,+6,+11）
Study NCT03171831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Thymoglobulin（2.5 mg/kg/day,4 days）
Study NCT03171831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Basiliximab（10mg on day 0 and +4）
Study NCT00835120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
Study NCT01389765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Administered orally
Study NCT00713726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FentanyL
Description: Fentanyl: 1 µg/kg/h for preterm infants and 2 µg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.